ライフサイエンスコーパス: refractory

1 either grade III to IV (30 patients, 33%) or refractory (12 patients, 13%) had a nonsignificant impac

2 2.6%) compared with those who were rituximab refractory (16.7%) (P = .04).

3 (8 persons [31%]), and not being medication refractory (8 persons [31%]).

4 ysregulated mouse model overexpressing a miR refractory acetylcholinesterase-R splice variant showed

5 Therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) re

6 vs usual care in adult patients with steroid-refractory acute GVHD.

7 herapy resistance for children with relapsed/refractory acute lymphoblastic leukemia (ALL).

8 eceptor-modified T cell therapy for relapsed/refractory acute lymphoblastic leukemia is leading to ex

9 tients following T cell therapy for relapsed/refractory acute lymphoblastic leukemia.

10 nd Aug 27, 2015, 252 adults with relapsed or refractory acute myeloid leukaemia received oral gilteri

11 t-naive acute myeloid leukaemia, relapsed or refractory acute myeloid leukaemia, and myelodysplastic

12 FLT3 inhibition in patients with relapsed or refractory acute myeloid leukaemia.

13 Ninety-five patients with relapsed or refractory acute myeloid leukemia (AML) were enrolled be

14 -2 is highly active in preclinical models of refractory acute myeloid leukemia (AML).

15 Glucocorticoid (GC)-refractory acute rejection (AR) is a risk factor for inf

16 e oxygenation may serve as rescue therapy in refractory acute respiratory distress syndrome but has n

17 over chemotherapy in patients with platinum-refractory advanced urothelial carcinoma.

18 IFN-alpha signaling is transient and becomes refractory after hours, whereas IFN-lambda provides a lo

19 The treatment of relapsed or refractory AITL remains an unmet need.

20 ods In this study, 26 patients with relapsed/refractory ALK-positive ALCL and 14 patients with metast

21 s a monotherapy in patients with relapsed or refractory AML and have informed subsequent phase 2 clin

22 mechanism of enasidenib efficacy in relapsed/refractory AML patients and provide insight into resista

23 Among patients with relapsed or refractory AML, overall response rate was 40.3%, with a

24 onotherapy dose in patients with relapsed or refractory AML.

25 r miR-7 as an RNA-based therapeutic to treat refractory and drug-resistant HCC.

26 Six patients were venetoclax refractory, and 23 had a complex karyotype and/or 17p de

27 performed on 1,362 samples-1,303 primary, 22 refractory, and 37 relapse samples.

28 61% were bortezomib and lenalidomide double refractory, and 46% had t(11;14).

29 RATIONALE: New therapies for refractory angina are needed.

30 Patients with refractory arrhythmic storm admitted between January 200

31 Patients with intractable refractory arrhythmic storm and cardiogenic shock despit

32 planted with extracorporeal life support for refractory arrhythmic storm responsible for cardiogenic

33 The most frequent indication for TIPS was refractory ascites (50 of 54; 93%).

34 urvival times of patients with cirrhosis and refractory ascites.

35 hma, many patients have poorly controlled or refractory asthma (RA).

36 t, asthma control and the presence of severe refractory asthma (SRA) were also recorded.

37 tment option in patients with severe therapy-refractory asthma that downregulates selectively structu

38 hildren (0.5-17 years) with severe treatment-refractory asthma.

39 sus standard care in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

40 pproved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-g

41 5 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia was co

42 erapeutic potential of SGN-CD19B in relapsed/refractory B-NHL.

43 in inducing disease regression in treatment-refractory breast cancer chest wall metastases but respo

44 stemic albumin bound paclitaxel in treatment-refractory breast cancer of the chest wall.

45 urse of quinacrine was effective in treating refractory cases.

46 nant during treatment with ustekinumab for a refractory CD and which ended in miscarriage.

47 ressive antitumor responses in patients with refractory CD19(+) B-cell malignancies but is often asso

48 international study, adults with relapsed or refractory, CD22-positive, Philadelphia chromosome (Ph)-

49 Refractory celiac disease type II (RCDII) is a severe co

50 Our analysis excluded subjects with refractory celiac disease, undergoing gluten challenge,

51 ort a further clinical trial of XEN-D0501 in refractory chronic cough.

52 Adult patients with relapsed or refractory chronic lymphocytic leukaemia (according to t

53 dult patients (>/=18 years) with relapsed or refractory chronic lymphocytic leukaemia requiring treat

54 previously treated patients with relapsed or refractory chronic lymphocytic leukaemia were enrolled f

55 le tolerability in patients with relapsed or refractory chronic lymphocytic leukaemia whose disease p

56 the management of patients with relapsed or refractory chronic lymphocytic leukaemia.

57 Sixteen relapsed or refractory classic HL patients were included.

58 outine histopathology studies and/or PCR for refractory colitis patients are suggested to diagnose CM

59 therapy have been proposed for patients with refractory Crohn's disease (CD) and fistulizing CD, resp

60 nal inflammation) in patients with treatment-refractory Crohn's disease.

61 ent in patients with severe H1-antihistamine-refractory CSU with angioedema.

62 Overexpression of REST in hormone-refractory CWR22Rv1 PCa cells significantly reduces Twis

63 de avidity within the full spectrum from RAI-refractory dedifferentiated to ATC.

64 usly identified a young adult with treatment-refractory depression and multiple suicide attempts with

65 olic abnormalities contributing to treatment-refractory depression is underrecognized.

66 be effective in the treatment of relapsed or refractory diffuse large B-cell lymphoma and follicular

67 ysis were baseline MTV (bMTV) (P < .001) and refractory disease (P = .003).

68 All patients had relapsed or refractory disease after previous treatment with a BCR s

69 27 patients were diagnosed with relapsed or refractory disease and 12 died.

70 reatment options for patients with rituximab-refractory disease are an important clinical need.

71 Relapsed/refractory disease at study entry, TP53 aberration, adva

72 innovations for countering heterogeneous and refractory disease by virtue of their ability to bind tw

73 Patients with PTCL with primary refractory disease or early relapse have extremely poor

74 patients can require colectomy for medically refractory disease or to treat colonic neoplasia.

75 Temporomandibular joint (TMJ) ankylosis is a refractory disease that is difficult to predictably trea

76 augICE for relapsed/refractory HL, bMTV and refractory disease were independent prognostic factors f

77 in seven (70%) of 10 patients with pazopanib-refractory disease, including one patients with RCC with

78 DCT as third-line or later therapy, platinum-refractory disease, mediastinal primary tumor site, nons

79 outcomes for some patients with relapsed and refractory disease, not all patients have access to thes

80 Patients were stratified by relapsed versus refractory disease, presence or absence of del(17p) or T

81 the critical roles that GAS6 and AXL play in refractory disease, this signaling axis represents an at

82 b-based option is reasonable for relapsed or refractory disease.

83 volume (TMTV) could detect early relapse or refractory disease.

84 of ibrutinib in a population with rituximab-refractory disease.

85 to identify imaging findings associated with refractory disease.

86 in particular effective agents to treat TKI-refractory disease.

87 of DOS, concluding that the turnover time of refractory DOS that Ksionzek et al present cannot be ded

88 patients with Crohn's disease and treatment-refractory, draining, complex perianal fistulas.

89 ctive response activity in patients with RAI-refractory DTC who experienced disease progression while

90 ubic (bcc) HEAs, particularly those based on refractory elements are promising for high-temperature a

91 ds as potential anticonvulsant compounds for refractory epilepsies.

92 we securely implicate PPP3CA in early-onset refractory epilepsy and further support the emerging rol

93 For refractory epilepsy, this surgical intervention offers m

94 from nine human participants with medically refractory epilepsy.

95 s, during the presurgical evaluation of drug-refractory epilepsy.

96 used as a non-pharmacological treatment for refractory epilepsy.

97 Eligibility included endocrine-refractory, estrogen receptor-positive metastatic breast

98 eyes with naive DME gained more vision than refractory eyes (P < 0.001), the predictive value of OCT

99 es were analysed in 31 consecutive medically refractory focal epilepsy patients, evaluated by stereo-

100 ilepsy surgery is an effective treatment for refractory focal epilepsy.

101 tion ECoG sampled at 2,048 Hz in people with refractory focal epilepsy.

102 nti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis.

103 77 patients with proton pump inhibitor (PPI)-refractory GERD were randomized to CNF or LNF.

104 eyes of consecutive patients with medically refractory GFCS and JOAG in a single-surgeon pediatric g

105 es of 360-degree trabeculotomy for medically refractory GFCS and JOAG.

106 Refractory giardiasis was associated with malaise (P = .

107 ing a minimally invasive surgical option for refractory glaucoma patients.

108 tion study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cel

109 Transplant-eligible patients with relapsed/refractory HL received 2 (cohort 1) or 3 (cohort 2) cycl

110 safety profile in patients with relapsed or refractory HL who did not receive allo-HCT.

111 pted therapy with BV and augICE for relapsed/refractory HL, bMTV and refractory disease were independ

112 rognostic factors for patients with relapsed/refractory Hodgkin lymphoma (HL) is essential for optimi

113 ) is indicated for patients with relapsed or refractory Hodgkin lymphoma (HL).

114 er, had histologically confirmed relapsed or refractory Hodgkin's lymphoma or anaplastic large-T-cell

115 Refractory hypotensive shock was fatal in 55 of 115 pati

116 itor (PI) ixazomib in patients with relapsed/refractory immunoglobulin light chain (AL) amyloidosis.

117 t has promising activity as a monotherapy in refractory indolent lymphomas.

118 effective approach to treat severe and drug-refractory infections after HSCT, including infections f

119 n a patient on peritoneal dialysis (PD) is a refractory injury accompanied by severe inflammation, pr

120 oimmune responses associated with antibiotic-refractory LA.

121 te plus romidepsin in patients with relapsed/refractory lymphoma.

122 reserved for patients with truly severe and refractory LyP.

123 ndrogen receptor (AR) signaling in a hormone-refractory manner.

124 te of 82% among 45 patients with relapsed or refractory mantle cell lymphoma (MCL), with manageable t

125 o Jan 5, 2016, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all pa

126 , bone-tissue engineering, drug delivery and refractory materials, and use molecular dynamics simulat

127 erall survival for patients with relapsed or refractory MCL receiving BR.

128 Conclusion In endocrine-refractory metastatic breast cancer, Z-endoxifen provide

129 phase II trial of patients with relapsed or refractory metastatic colorectal cancer.

130 We enrolled patients with treatment-refractory metastatic SCCA, who were given nivolumab eve

131 multicenter trial in patients with relapsed/refractory metastatic TNBC who received a 10 mg/kg start

132 nd 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma.

133 er, phase 2 study, 48 patients with relapsed/refractory MM (RRMM) received 28-day cycles of pembroliz

134 on-free survival can be achieved in relapsed/refractory MM patients when CD38 antibodies are combined

135 n this phase 1 study, patients with relapsed/refractory MM received venetoclax monotherapy.

136 hase 1b trial studied patients with relapsed/refractory MM receiving daily venetoclax (50-1200 mg per

137 timyeloma activity in patients with relapsed/refractory MM, predominantly in patients with t(11;14) a

138 promising efficacy in patients with relapsed/refractory MM.

139 IL17A levels were more likely to be found in refractory MPP children or in MPP children with pleural

140 ies are needed for patients with relapsed or refractory multiple myeloma (MM).

141 ation in patients with relapsed lenalidomide-refractory multiple myeloma (MM).

142 ns have become available for relapsed and/or refractory multiple myeloma (R/R MM) after a long period

143 hasone 40 mg (QW), in patients with relapsed/refractory multiple myeloma (RRMM).

144 ts with both newly diagnosed and relapsed or refractory multiple myeloma because it assesses bone dam

145 patients with newly diagnosed or relapsed or refractory multiple myeloma who were treated in clinical

146 dex) was evaluated in patients with relapsed/refractory multiple myeloma with >/=2 prior lines of the

147 were aged 18 years or older, had relapsed or refractory multiple myeloma, and had received between on

148 some inhibitors in patients with relapsed or refractory multiple myeloma.

149 e and effective option for improving severe, refractory multiple sclerosis tremor.

150 by the Food and Drug Administration to treat refractory multiple sclerosis.

151 ltimethod HIVDR analysis using amplification-refractory mutation system (ARMS)-PCR, Sanger sequencing

152 t as a regimen for patients with relapsed or refractory myeloma undergoing an autologous stem-cell tr

153 ed with DEX implant for DME (naive, n = 209; refractory, n = 90).

154 tumour activity in patients with relapsed or refractory neuroblastoma.

155 an-temozolomide in patients with relapsed or refractory neuroblastoma.

156 nophilic lung inflammation to corticosteroid-refractory neutrophilic manifestation.

157 e radiosurgical procedure for many treatment-refractory OCD patients.

158 treatable CAD was prevalent in patients with refractory OH VF/VT cardiac arrest who also met criteria

159 (18)F-FDG PET data from patients with refractory or advanced disease demonstrated CMR in more

160 ts with active rheumatoid arthritis who were refractory or intolerant to anti-TNF drugs and other bio

161 and purine analogs are suitable options for refractory or multiply relapsed WM.

162 Patients with lymphoma that is chemotherapy refractory or relapsed after autologous stem-cell transp

163 -cell immunotherapy is a novel treatment for refractory or relapsed B-cell malignancies.

164 We enrolled patients with primary refractory or relapsed myeloma who had received treatmen

165 and active regimen for ASCT in patients with refractory or relapsed myeloma.

166 ector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC.

167 ary artery disease (CAD) among patients with refractory out-of-hospital (OH) ventricular fibrillation

168 on therapy for the treatment of chemotherapy-refractory pancreatic cancer.

169 comitant restoration of iodide uptake in RAI-refractory papillary and follicular thyroid cancer cell

170 Median overall survival among relapsed/refractory patients was 9.3 months, and for the 34 patie

171 red with chemotherapy regimens in ipilimumab-refractory patients with advanced melanoma.

172 RLT was performed in 40 hormone-refractory patients with distant metastases and progress

173 initiated, the clinical use of ipilimumab in refractory patients with unmet medical needs could warra

174 y consistent across subgroups (58% in double-refractory patients).

175 the management of many severe and treatment-refractory patients.

176 The ORR was 52% in 42 evaluable lenalidomide-refractory patients.

177 body, nivolumab, in 4 patients with relapsed/refractory PCNSL and 1 patient with CNS relapse of PTL.

178 suggest that nivolumab is active in relapsed/refractory PCNSL and PTL and support further investigati

179 ) activation of a signaling component with a refractory period (e.g. G protein), and 3) inactivation

180 n (APD), conduction velocity (CV), effective refractory period (ERP), tissue excitation threshold and

181 From each VRC was measured the relative refractory period (RRP), the supernormality and the time

182 ton arrival and emergence of a QB), and (iv) refractory period distribution (time for a microvillus t

183 RATIONALE: The development of a refractory period for Ca(2+) spark initiation after Ca(2

184 nged action potential duration and effective refractory period, decreased LSG function were identifie

185 t transformations, for example thresholds or refractory periods.

186 vedotin have been approved for relapsed and refractory peripheral T-cell lymphomas based on their ac

187 ive, is an environmental contaminant that is refractory, persistent, highly mobile in soils and aquif

188 ic CTLs are capable of controlling treatment-refractory Ph(+) ALL in vivo, and support the developmen

189 of blinatumomab in patients with relapsed or refractory Ph(+) ALL.

190 acy of pegylated ADI (ADI-PEG20) in relapsed/refractory/poor-risk acute myeloid leukemia (AML) was ev

191 y provide a therapeutic opportunity for this refractory population.

192 f secondary proctectomies were performed for refractory proctitis, and 20% for rectal neoplasia.

193 promising clinical benefit in patients with refractory, progressive desmoid tumors who receive long-

194 Nerve refractory properties were not affected.

195 IL-23-TH17-pathway as a treatment option for refractory PRP.

196 re taken from this patient and 2 others with refractory PRP.

197 ug Administration for patients with relapsed/refractory PTCL, exhibiting response rates of 25% and 29

198 salvage therapy in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL).

199 Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor

200 tuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma

201 Patients with platinum-refractory recurrent or metastatic squamous cell carcino

202 arding outcomes of patients with relapsed or refractory (rel/ref) DEL or DHL who undergo autologous s

203 due to its propensity for early invasion and refractory relapse after initial treatment response.

204 oid leukemia (AML) patients, particularly in refractory/relapse (RR) population.

205 Pre-therapy plasma of refractory/relapsed AML patients contains elevated level

206 el ZNF767-BRAF fusion found in a vemurafenib-refractory respiratory tract PMM, from which cell line h

207 Refractory responses requiring antibiotic therapy result

208 -363 was abundantly expressed in relapse and refractory samples, and several candidate targets of miR

209 Affected individuals suffer from refractory seizures, developmental delay, cognitive disa

210 y department between 2009 and 2015 for fluid-refractory severe sepsis or septic shock.

211 eal membrane oxygenation, if available, when refractory shock has a significant cardiogenic component

212 h sera from patients and mtDNA, reproduced a refractory state after endotoxin challenge.

213 t monocytes from patients with AIS exhibit a refractory state or endotoxin tolerance.

214 trol the evolution of human monocytes into a refractory state: IL-1R-associated kinase-M, NFkB2/p100,

215 Super-refractory status epilepticus (SRSE) is a life-threateni

216 Super-refractory status epilepticus is a condition characteriz

217 of a 17-year-old boy with a prolonged super-refractory status epilepticus that eventually resolved a

218 imulation may be a treatment option in super-refractory status epilepticus when other treatment optio

219 force-sensing catheter for ablation of drug refractory, symptomatic paroxysmal atrial fibrillation i

220 The management of drug-refractory symptoms of obstructive hypertrophic cardiomy

221 A patient with refractory T-ALL was treated with dasatinib on the basis

222 clax treatment was commenced in 2 late-stage refractory T-PLL patients resulting in clinical response

223 and an acceptable safety profile in relapsed/refractory TCL, as well as preclinical evidence of both

224 I dosimetry in a patient who had radioiodine-refractory thyroid cancer and who underwent a redifferen

225 y in cell line and xenograft models that are refractory to ADCs comprised of the individual auristati

226 Applied to acquired nystagmus refractory to all other interventions, it is shown succe

227 th paroxysmal atrial fibrillation, which was refractory to antiarrhythmic drugs.

228 persistent intracellular reservoirs that are refractory to antibiotic treatments.

229 of patients suffering a severely active CSU refractory to antihistamine treatment.

230 ith Ph(+) ALL who had relapsed after or were refractory to at least one second-generation or later TK

231 omplex diseases, many of which are currently refractory to available therapeutics (e.g., hypertension

232 ituents of distinct subcellular compartments refractory to biochemical isolation and reveal VRK2A as

233 7% and >/=VGPR 73% were seen in patients not refractory to bortezomib who had 1 to 3 prior therapies.

234 melphalan group by sex, age, disease status, refractory to both proteasome inhibitors and immunomodul

235 proteasome inhibitor: (35 [73%] of 48) were refractory to both; (31 [70%]) had received an autologou

236 Metastatic, therapy-resistant BC cells are refractory to cell death induced by multiple stresses.

237 ure and dynamics of the FG-network have been refractory to characterization due to the paucity of exp

238 combat infectious diseases that have proven refractory to classical approaches.

239 so enables processing of substrates normally refractory to cleavage.

240 y with multiple seizure types that are often refractory to conventional therapies.

241 rophilia also correlates with asthma that is refractory to corticosteroids, the mainstay of asthma tr

242 human cancers, but the vast majority remains refractory to current clinical therapies.

243 harboring mutant BRAF/PTEN, which often are refractory to current therapies.

244 TgD expressing deer PrP(C) was similarly refractory to deer prions from diseased TgD infected wit

245 colysis-deficient mutant, while TgPEPCKmt is refractory to deletion.

246 inical productive infection with MARV but is refractory to EBOV.

247 mor, is propagated by stem-like cancer cells refractory to existing therapies.

248 Mature ECs lack EGF receptors and are refractory to growth signalling.

249 HIV-1 intasomes have been refractory to high-resolution structural studies.

250 th the potential to be effective in patients refractory to ibrutinib.

251 ted during prolonged antigen exposure remain refractory to ICB-mediated rejuvenation.

252 d-generation or later TKIs and intolerant or refractory to imatinib.

253 In various models of solid cancers refractory to immunotherapies, including hepatocellular

254 pelin receptor, in patient tumours that were refractory to immunotherapy.

255 t expression is intrinsic, as stem cells are refractory to interferon.

256 These findings reveal that cells refractory to invasion can still be injected, thus exten

257 isters, cells with decreased metabolic rate, refractory to killing by these drugs, and able to genera

258 ose with symptoms or treatment complications refractory to medical management.

259 ich contains melanocyte stem cells, was also refractory to melanomagenesis.

260 interferon [IFN-gamma]) and rendered T cells refractory to mitogen for a least 18 h after transient e

261 y, coupled with a backbone structure that is refractory to nuclease digestion, makes TNA an attractiv

262 Patients refractory to ofatumumab were excluded.

263 However, patients who are refractory to or relapse after ibrutinib therapy have po

264 rom 60% to 70%, up to 50% of patients become refractory to or relapse after treatment.

265 A BSG knockout was completely refractory to parasite invasion in a strain-transcendent

266 static head and neck squamous cell carcinoma refractory to platinum and cetuximab.

267 Three of the responders were refractory to previous immune checkpoint blockade.

268 s (median 5 [range 1-12] prior regimens; 83% refractory to previous lenalidomide therapy) were treate

269 follicular lymphoma that had relapsed or was refractory to previous treatments.

270 prior therapies (range, 1-13); 26 (39%) were refractory to prior bortezomib and 35 (53%) to lenalidom

271 ng brain, heart, and kidneys, are profoundly refractory to pro-apoptotic signaling, leading to cellul

272 es regeneration of non-alpha-RGCs, which are refractory to Pten deletion-induced regeneration.

273 ght near human hosts [6], and females become refractory to remating within seconds [1, 3, 4], suggest

274 cute myeloid leukemia (AML) whose disease is refractory to standard induction chemotherapy therapy or

275 luten-free diet and dapsone, treatment of DH refractory to standard treatments is not well defined.

276 xtramammary Paget disease (EMPD) is commonly refractory to surgical and nonsurgical therapies.

277 ly intoxicated by BoNT serotypes D or E were refractory to synaptic rescue by any treatment.

278 nts were enrolled, all with liver metastases refractory to systemic therapy and ineligible for surgic

279 Notably, these cells were refractory to telomerase inhibitors, indicating recombin

280 Committed gametocytes are refractory to the commonly used drug piperaquine, and ma

281 ma with >/=2 prior lines of therapy who were refractory to their last treatment.

282 d neck squamous cell carcinomas (HNSCCs) are refractory to therapeutic interventions.

283 For patients with symptoms that are refractory to these initial treatment options and those

284 ide, that can be considered in CAPS patients refractory to traditional treatment.

285 f higher-order chromatin structures that are refractory to transcription but not fully understood.

286 for patients with disease that is otherwise refractory to treatment.

287 -/-) Shp(-/-) double knockout (DKO) mice are refractory to weight gain, glucose intolerance, and hepa

288 TDPD demonstrated improvements in medication-refractory tremor by CRST assessments, even in the setti

289 They also suggest strategies for eliminating refractory tumor cells by targeting epigenetic and devel

290 onses in pazopanib- and other VEGF inhibitor-refractory tumors, which supports epigenetically mediate

291 Advanced therapies for pump failure or refractory VAs, including heart transplantation and dura

292 antation had a better survival than those in refractory ventricular fibrillation (p = 0.017).

293 November 2015, five patients with high-risk, refractory ventricular tachycardia underwent treatment.

294 hospital discharge in patients experiencing refractory VF/VT cardiac arrest treated with a novel pro

295 rable trends from treatment of initial shock-refractory VF/VT with these drugs.

296 randomized on subsequently developing shock-refractory VF/VT.

297 NK cell deficiency can result in severe or refractory viral infections.

298 Patients with SHD who underwent CSD for refractory VT or VT storm at 5 international centers wer

299 VT and ICD shock recurrence in patients with refractory VT.

300 ts present with hypogammaglobulinemia and/or refractory warts of skin and genitalia.